FX.co ★ Amgen Reports Positive Phase 3 Data For Uplizna In Generalized Myasthenia Gravis

Amgen Inc. (AMGN) announced on Tuesday that the Phase 3 MINT study has delivered positive topline results for Uplizna, demonstrating its efficacy in treating adults with generalized myasthenia gravis, a rare autoimmune condition. The study successfully achieved its primary objective.

The main goal of the study was to evaluate changes from baseline in the Myasthenia Gravis Activities of Daily Living (MG-ADL) score, which measures the impact of myasthenia gravis symptoms on daily life activities. The study included both acetylcholine receptor autoantibody-positive (AChR+) patients and muscle-specific kinase autoantibody-positive (MuSK+) patients, as these antibodies are present in individuals suffering from the disease.

The findings indicated that Uplizna provided both clinically meaningful and statistically significant improvements in patients with AChR+ and MuSK+ antibodies.

These significant results are slated for presentation at the Myasthenia Gravis Foundation of America (MGFA) Scientific Session, part of the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting, scheduled for October 15-18 in Savannah, Georgia.

Notably, Uplizna is already approved for treating neuromyelitis optica spectrum disorder (NMOSD), another rare autoimmune disease affecting the central nervous system.